JP2015512420A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512420A5
JP2015512420A5 JP2015503653A JP2015503653A JP2015512420A5 JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5 JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5
Authority
JP
Japan
Prior art keywords
use according
hyperalgesia
drug
peripheral neuropathy
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503653A
Other languages
English (en)
Japanese (ja)
Other versions
JP6317324B2 (ja
JP2015512420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/034647 external-priority patent/WO2013149172A1/en
Publication of JP2015512420A publication Critical patent/JP2015512420A/ja
Publication of JP2015512420A5 publication Critical patent/JP2015512420A5/ja
Application granted granted Critical
Publication of JP6317324B2 publication Critical patent/JP6317324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503653A 2012-03-30 2013-03-29 神経障害を予防および処置するための方法および組成物 Active JP6317324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618428P 2012-03-30 2012-03-30
US61/618,428 2012-03-30
PCT/US2013/034647 WO2013149172A1 (en) 2012-03-30 2013-03-29 Methods and compositions for the prevention and treatment neuropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018063574A Division JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015512420A JP2015512420A (ja) 2015-04-27
JP2015512420A5 true JP2015512420A5 (enExample) 2016-05-26
JP6317324B2 JP6317324B2 (ja) 2018-04-25

Family

ID=49261299

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503653A Active JP6317324B2 (ja) 2012-03-30 2013-03-29 神経障害を予防および処置するための方法および組成物
JP2018063574A Pending JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018063574A Pending JP2018123143A (ja) 2012-03-30 2018-03-29 神経障害を予防および処置するための方法および組成物

Country Status (8)

Country Link
US (5) US9636378B2 (enExample)
EP (3) EP3170506B1 (enExample)
JP (2) JP6317324B2 (enExample)
CN (2) CN107320712A (enExample)
AU (2) AU2013237827B2 (enExample)
CA (1) CA2869080C (enExample)
DK (1) DK2830644T3 (enExample)
WO (1) WO2013149172A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2013149172A1 (en) 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
EP3500286A4 (en) * 2016-08-16 2020-03-25 Stealth BioTherapeutics Corp N-CARBOXYANHYDRIDE-BASED ELAMIPRETIDE SCALE SYNTHESIS
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN112961249B (zh) * 2021-02-25 2023-08-04 兰州大学 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用
WO2024253189A1 (ja) * 2023-06-09 2024-12-12 国立大学法人 富山大学 がん化学療法剤に起因する末梢神経障害の予防剤及び/又は改善剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913318A (ja) 1982-07-13 1984-01-24 株式会社村田製作所 電子部品の製造方法
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
PT1599216E (pt) * 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
NZ549393A (en) 2004-01-23 2009-07-31 Cornell Res Foundation Inc Methods for reducing oxidative damage
KR20150013353A (ko) * 2005-09-16 2015-02-04 코넬 리서치 화운데이션,인크. Cd36 발현을 감소시키는 방법
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
EP4302829B1 (en) * 2009-08-24 2025-05-21 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
JP2013516425A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 血管閉塞傷害の予防または治療方法
JP2013516426A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
EP2528934A4 (en) * 2010-01-25 2013-08-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
KR101351432B1 (ko) 2011-12-27 2014-01-15 에스케이씨 주식회사 초미세 발포 폴리우레탄 탄성체의 제조방법
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy

Similar Documents

Publication Publication Date Title
JP2015512420A5 (enExample)
JP2010270124A5 (enExample)
HK1247835A1 (zh) 甲状旁腺功能减退症的治疗
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
JP2013527232A5 (enExample)
JP2016512506A5 (enExample)
BR112013022044A2 (pt) veículo mastigável para absorção na boca
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
EA201490254A1 (ru) Комбинированное лечение гепатита с
JP2019521180A5 (enExample)
JP2013542205A5 (enExample)
JP2011515481A5 (enExample)
BR112015010396A2 (pt) terapia de combinação
JP2013509441A5 (enExample)
WO2009120697A4 (en) Method and compositions for treatment of cancer
JP2016530291A5 (enExample)
RU2015137455A (ru) Пероральная антисептическая композиция для лечения мукозита слизистой оболочки полости рта
RU2013155509A (ru) Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
CO6341514A2 (es) Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica
JP2018522028A5 (enExample)
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres